(DHR) Danaher - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 121.114m USD | Total Return: -8% in 12m

Bioprocessing Equipment, Analytical Instruments, Medical Diagnostics
Total Rating 40
Safety 75
Buy Signal -0.71
Diagnostics & Research
Industry Rotation: +1.9
Market Cap: 121B
Avg Turnover: 800M
Risk 3d forecast
Volatility24.9%
VaR 5th Pctl4.22%
VaR vs Median3.09%
Reward TTM
Sharpe Ratio-0.24
Rel. Str. IBD11.4
Rel. Str. Peer Group23.8
Character TTM
Beta0.478
Beta Downside0.596
Hurst Exponent0.453
Drawdowns 3y
Max DD41.72%
CAGR/Max DD-0.11
CAGR/Mean DD-0.30
EPS (Earnings per Share) EPS (Earnings per Share) of DHR over the last years for every Quarter: "2021-03": 2.52, "2021-06": 2.46, "2021-09": 2.39, "2021-12": 2.69, "2022-03": 2.76, "2022-06": 2.76, "2022-09": 2.56, "2022-12": 2.87, "2023-03": 2.36, "2023-06": 2.05, "2023-09": 2.02, "2023-12": 2.09, "2024-03": 1.92, "2024-06": 1.72, "2024-09": 1.71, "2024-12": 1.49, "2025-03": 1.88, "2025-06": 1.8, "2025-09": 1.89, "2025-12": 2.23, "2026-03": 2.06,
EPS CAGR: -8.67%
EPS Trend: -68.1%
Last SUE: 0.79
Qual. Beats: 0
Revenue Revenue of DHR over the last years for every Quarter: 2021-03: 6858, 2021-06: 7218, 2021-09: 7229, 2021-12: 8148, 2022-03: 7688, 2022-06: 7751, 2022-09: 7663, 2022-12: 7134, 2023-03: 5949, 2023-06: 7157, 2023-09: 5624, 2023-12: 6405, 2024-03: 5796, 2024-06: 5743, 2024-09: 5798, 2024-12: 6538, 2025-03: 5741, 2025-06: 5936, 2025-09: 6053, 2025-12: 6838, 2026-03: 5951,
Rev. CAGR: -3.00%
Rev. Trend: -57.8%
Last SUE: -0.29
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: DHR Danaher

Danaher Corporation (DHR) is a global life sciences and diagnostics innovator operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. The company provides essential tools, consumables, and software used in the development of therapeutics, genomic medicine, and clinical disease diagnosis. Following the spin-off of its environmental and applied solutions business (Veralto) in 2023, Danaher has transitioned into a pure-play health care technology company.

The business model relies heavily on a razor-and-blade strategy, where the placement of high-end instrumentation drives long-term, recurring revenue through specialized consumables and reagents. This model is particularly effective in the bioprocessing sector, where Danaher’s technologies are integrated into the highly regulated manufacturing workflows of biologic drugs. The company utilizes the Danaher Business System (DBS), a lean management philosophy derived from kaizen principles, to drive operational efficiency and continuous improvement across its diverse portfolio of brands.

Further analysis of Danahers valuation metrics and historical performance is available on ValueRay for those conducting deeper due diligence.

Headlines to Watch Out For
  • Bioprocessing demand recovery accelerates revenue growth in the core Biotechnology segment
  • Recurring consumables revenue provides high-margin stability across Diagnostics and Life Sciences
  • Strategic mergers and acquisitions drive portfolio expansion through the Danaher Business System
  • Healthcare spending and clinical testing volumes dictate Diagnostic segment organic growth
  • Research and development funding levels impact capital equipment sales in Life Sciences
Piotroski VR-10 (Strict) 6.5
Net Income: 3.69b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.14 > 1.0
NWC/Revenue: 26.13% < 20% (prev 12.09%; Δ 14.04% < -1%)
CFO/TA 0.08 > 3% & CFO 6.44b > Net Income 3.69b
Net Debt (14.1b) to EBITDA (6.69b): 2.10 < 3
Current Ratio: 1.87 > 1.5 & < 3
Outstanding Shares: last quarter (711.2m) vs 12m ago -1.33% < -2%
Gross Margin: 60.68% > 18% (prev 0.60%; Δ 6.01k% > 0.5%)
Asset Turnover: 30.47% > 50% (prev 30.11%; Δ 0.36% > 0%)
Interest Coverage Ratio: 18.13 > 6 (EBITDA TTM 6.69b / Interest Expense TTM 256.0m)
Altman Z'' 4.37
A: 0.08 (Total Current Assets 13.9b - Total Current Liabilities 7.46b) / Total Assets 83.5b
B: 0.57 (Retained Earnings 47.6b / Total Assets 83.5b)
C: 0.06 (EBIT TTM 4.64b / Avg Total Assets 81.3b)
D: 1.54 (Book Value of Equity 47.1b / Total Liabilities 30.6b)
Altman-Z'' = 4.37 = AA
Beneish M -3.19
DSRI: 0.85 (Receivables 3.82b/4.31b, Revenue 24.8b/23.8b)
GMI: 0.99 (GM 60.68% / 59.80%)
AQI: 0.96 (AQ_t 0.77 / AQ_t-1 0.80)
SGI: 1.04 (Revenue 24.8b / 23.8b)
TATA: -0.03 (NI 3.69b - CFO 6.44b) / TA 83.5b)
Beneish M = -3.19 (Cap -4..+1) = AA
What is the price of DHR shares?

As of May 27, 2026, the stock is trading at USD 172.81 with a total of 3,283,135 shares traded.
Over the past week, the price has changed by +5.46%, over one month by -4.32%, over three months by -17.28% and over the past year by -8.02%.

Is DHR a buy, sell or hold?

Danaher has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy DHR.

  • StrongBuy: 19
  • Buy: 4
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the DHR price?
Analysts Target Price 247.8 43.4%
Danaher (DHR) - Fundamental Data Overview as of 22 May 2026
Market Cap USD = 121b (121b USD * 1.0 USD.USD)
P/E Trailing = 33.0986
P/E Forward = 19.7628
P/S = 4.888
P/B = 2.2328
P/EG = 1.0685
Revenue TTM = 24.8b USD
EBIT TTM = 4.64b USD
EBITDA TTM = 6.69b USD
Long Term Debt = 17.6b USD (from longTermDebt, last quarter)
Short Term Debt = 923.0m USD (from shortTermDebt, last quarter)
Debt = 19.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.28b
Net Debt = 14.1b USD (calculated: Debt 19.8b - CCE 5.70b)
Enterprise Value = 135b USD (121b + Debt 19.8b - CCE 5.70b)
Interest Coverage Ratio = 18.13 (Ebit TTM 4.64b / Interest Expense TTM 256.0m)
EV/FCF = 25.55x (Enterprise Value 135b / FCF TTM 5.29b)
FCF Yield = 3.91% (FCF TTM 5.29b / Enterprise Value 135b)
FCF Margin = 21.35% (FCF TTM 5.29b / Revenue TTM 24.8b)
Net Margin = 14.89% (Net Income TTM 3.69b / Revenue TTM 24.8b)
Gross Margin = 60.68% ((Revenue TTM 24.8b - Cost of Revenue TTM 9.74b) / Revenue TTM)
Gross Margin QoQ = 60.34% (prev 58.00%)
Tobins Q-Ratio = 1.62 (Enterprise Value 135b / Total Assets 83.5b)
Interest Expense / Debt = 1.30% (Interest Expense 256.0m / Debt 19.8b)
Taxrate = 16.68% (206.0m / 1.24b)
NOPAT = 3.87b (EBIT 4.64b * (1 - 16.68%))
Current Ratio = 1.87 (Total Current Assets 13.9b / Total Current Liabilities 7.46b)
Debt / Equity = 0.37 (Debt 19.8b / totalStockholderEquity, last quarter 52.9b)
Debt / EBITDA = 2.10 (Net Debt 14.1b / EBITDA 6.69b)
Debt / FCF = 2.66 (Net Debt 14.1b / FCF TTM 5.29b)
Total Stockholder Equity = 52.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.54% (Net Income 3.69b / Total Assets 83.5b)
RoE = 7.06% (Net Income TTM 3.69b / Total Stockholder Equity 52.2b)
RoCE = 6.65% (EBIT 4.64b / Capital Employed (Equity 52.2b + L.T.Debt 17.6b))
RoIC = 5.31% (NOPAT 3.87b / Invested Capital 72.9b)
WACC = 6.74% (E(121b)/V(141b) * Re(7.66%) + D(19.8b)/V(141b) * Rd(1.30%) * (1-Tc(0.17)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -2.11%
[DCF] Terminal Value 76.43% ; FCFF base≈5.14b ; Y1≈5.50b ; Y5≈6.61b
[DCF] Fair Price = 123.5 (EV 102b - Net Debt 14.1b = Equity 87.4b / Shares 707.8m; r=8.35% [WACC [floored]]; 5y FCF grow 7.94% → 2.50% )
EPS Correlation: -68.09 | EPS CAGR: -8.67% | SUE: 0.79 | # QB: 0
Revenue Correlation: -57.76 | Revenue CAGR: -3.00% | SUE: -0.29 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.83 | Chg30d=-1.59% | Revisions=-60% | Analysts=21
EPS next Quarter (2026-09-30): EPS=2.03 | Chg30d=-2.10% | Revisions=-81% | Analysts=21
EPS current Year (2026-12-31): EPS=8.44 | Chg30d=+0.41% | Revisions=+75% | GrowthEPS=+8.2% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=9.09 | Chg30d=-0.05% | Revisions=-24% | GrowthEPS=+7.8% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: -81%